drugset / Trial / NCT05171049
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Timeline
- Start
- 2022-05-05
- Primary completion
- 2026-02-04
- Completion
- 2026-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abelacimab | Monoclonal antibody | 150 mg | Intravenous |
| Comparator | Apixaban | Small molecule | 5 mg | Oral |